文献速递复苏、休克与脓毒症消化、代谢与肾脏急症

规范处置仍难治的过敏反应致心脏骤停

Cardiac Arrest Caused by Anaphylaxis Refractory to Prompt Management.
PubMed 文献 · Am J Emerg Med · 2022-08-21
一句话结论过敏反应患者即便在院内被迅速识别并按流程处置,仍可能在数分钟内进展为心脏骤停;作者认为对潜在致死性表现应采取更积极策略,包括静脉输注肾上腺素。

该研究回顾2017年1月至2021年5月因疑似院内过敏反应转诊至急诊科的患者病历,按本院过敏反应流程在院内立即给予肾上腺素、糖皮质激素和抗组胺药。研究期间共评估246例疑似过敏反应,236例符合过敏反应诊断标准,其中178例出现休克征象,6例(2.5%)发生心脏骤停。6例中3例在入急诊科前恢复自主循环,2例虽在急诊科复苏仍死于难治性心脏骤停;1例接受体外心肺复苏后经包括温度管理在内的心脏骤停后治疗存活且神经功能完好。作者据此强调难治性过敏反应导致院内心脏骤停的风险,并认为对潜在致死性表现应采取更积极策略。

要点

  • 236例符合过敏反应诊断的患者中178例出现休克征象,6例(2.5%)发生心脏骤停。
  • 6例心脏骤停中3例入急诊科前恢复自主循环,2例在急诊科复苏后仍死于难治性心脏骤停。
  • 1例接受体外心肺复苏并完成包括温度管理在内的心脏骤停后治疗,存活且神经功能完好。
  • 作者指出患者可在被迅速识别和处置后数分钟内进展为心脏骤停。
  • 作者认为对潜在致死性症状应采取更积极策略,包括静脉输注肾上腺素。

适用人群与场景

  • 因疑似院内过敏反应转诊至急诊科的患者,研究时段为2017年1月至2021年5月。
  • 研究期间共评估246例疑似过敏反应,其中236例符合过敏反应诊断标准,178例出现休克征象。

诊断标准与关键阈值

  • 难治性过敏反应定义为:即使遵循过敏反应流程处置,仍发生过敏反应所致心脏骤停。

处置流程与药物剂量

  • 按本院过敏反应流程,在研究时段前即在院内现场立即给予肾上腺素、糖皮质激素和抗组胺药。
  • 作者认为,若患者出现潜在致死性症状,应采取更积极策略,包括静脉输注肾上腺素。
  • 对心脏骤停后患者实施心脏骤停后治疗,包括温度管理;1例接受体外心肺复苏者经此治疗后存活且神经功能完好。

红旗征与不能漏的情况

  • 过敏反应所致心脏骤停:即使迅速识别并按流程处置,仍可能在数分钟内发生。

研究设计与关键结果

  • 研究为对2017年1月至2021年5月急诊科疑似院内过敏反应患者病历的回顾,共评估246例,236例符合过敏反应诊断标准。
  • 236例中178例出现休克征象,6例(2.5%)发生心脏骤停。
  • 6例心脏骤停中,3例在入急诊科前恢复自主循环,2例在急诊科复苏后仍死于难治性心脏骤停。
  • 1例接受体外心肺复苏,经包括温度管理在内的心脏骤停后治疗存活且神经功能完好。

证据类型、等级与局限

  • 证据类型:病例系列(回顾性病历复习),附文献复习。
  • 局限:原文未报告局限性

对床旁实践的改变

  • 作者强调难治性过敏反应导致院内心脏骤停的风险,提示即使迅速识别和处置,患者仍可能在数分钟内进展为心脏骤停。
  • 作者认为,对出现潜在致死性症状的患者,应采取更积极的策略,包括静脉输注肾上腺素。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Anaphylaxis is a potentially life-threatening condition that occurs in the emergency department (ED). Although anaphylaxis is rapidly recognized and treated in the hospital compared with that in the community, in some cases, it does not respond to proper management.

OBJECTIVE: The aim of this study is to describe our experience of cases of refractory anaphylaxis leading to cardiac arrest in hospital, to review their characteristics compared with those seen in the community, and to discuss the best management practices for anaphylaxis-induced cardiac arrest with a literature review.

METHODS: We reviewed the medical records of patients referred to the ED with possible in-hospital anaphylaxis between January 2017 and May 2021. According to the anaphylaxis protocol, epinephrine, corticosteroid, and antihistamine were administered immediately on-site at our institution before the study period. Refractory anaphylaxis was defined as the development of anaphylaxis-induced cardiac arrest even after following the anaphylaxis protocol.

RESULTS: A total of 246 cases were evaluated for possible anaphylaxis, with 236 cases meeting the criteria for a diagnosis of anaphylaxis. Among them, 178 patients showed the signs and symptoms of shock, and cardiac arrest occurred in 6 patients (2.5%). Of the six patients, three had a return of spontaneous circulation before admission to the ED, while two died due to refractory cardiac arrest despite resuscitation in the ED. Following post-cardiac arrest care, including temperature management, one patient who received extracorporeal cardiopulmonary resuscitation survived neurologically intact.

CONCLUSION: We present our case series to highlight the risk of developing refractory anaphylaxis with subsequent in-hospital cardiac arrest. Patients may progress to cardiac arrest within minutes despite prompt recognition and management. If patients present with potentially fatal symptoms, a more aggressive approach, including intravenous adrenaline infusion, should be taken.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Park H, Kim SM, Kim WY, et al. Cardiac Arrest Caused by Anaphylaxis Refractory to Prompt Management. Am J Emerg Med. 2022. PMID: 36057212. doi:10.1016/j.ajem.2022.08.035

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。